Research output per year
Research output per year
Personal profile
Research interests
I gained a PhD in epidemiology in 2002 and have been working in long-term observational research since then. The Biologic Studies Group hosts a series of real-world studies looking at the long-term safety of new drugs for inflammatory disesaes including rheumatoid arthritis, juvenile idiopathic arthritis and lupus in both adults and children.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Kath Watson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.
Kearsley-Fleet, L., Rokad, A., Tsoi, M. F., Zhao, S., Lunt, M., Watson, K., BSRBR-RA Contributors Group & Hyrich, K., 14 Mar 2023, (Accepted/In press) In: Rheumatology (Print).Research output: Contribution to journal › Article › peer-review
-
Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
BSRBR-RA Contributors Group, 10 May 2022, In: Rheumatology (Print). keac190.Research output: Contribution to journal › Article › peer-review
Open Access -
Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
BSRBR-RA Control Centre Consortium, 5 Aug 2019, In: Rheumatology (Oxford).Research output: Contribution to journal › Article › peer-review
Open Access -
Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register
Fagerli, K. M., Kearsley-Fleet, L., Mercer, L. K., Watson, K., Packham, J., Symmons, D. P. M., Hyrich, K. L. & British Society for Rheumatology Biologics Register, 1 Jan 2019, In: Rheumatology (Oxford, England). 58, 1, p. 80-85Research output: Contribution to journal › Article › peer-review
Open Access -
Biologic Refractory Disease in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Kearsley-Fleet, L., Davies, R., De Cock, D., Watson, K., Lunt, M., Buch, M., Isaacs, J. D., Hyrich, K. & BSRBR-RA Contributors Group, Oct 2018, In: Annals of the rheumatic diseases. 77, 10, p. 1405-1412Research output: Contribution to journal › Article › peer-review
Open Access
Projects
-
BCRD/BSPAR: UK JIA Biologics Registers: the BCRD and BSPAR Etanercept Studies
Hyrich, K., Mowbray, K., Kearsley-Fleet, L., Sutton, E. & Watson, K.
Project: Research
-
British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR-RA)
Hyrich, K., Watson, K., Mowbray, K., Kearsley-Fleet, L., Lunt, M. & Verstappen, S.
Project: Research